Biogen Idec Inc. (BIIB)
-NasdaqGS 210.80 
3.05(1.47%) 04:00 SGT|After Hours
:
210.81 0.01 (0.00%) 06:42 SGT
| Prev Close: | 207.75 |
|---|
| Open: | 207.51 |
|---|
| Bid: | 200.00 x 100 |
|---|
| Ask: | 217.39 x 100 |
|---|
| 1y Target Est: | 235.71 |
|---|
| Beta: | 1.23 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 206.43 - 211.62 |
|---|
| 52wk Range: | 134.00 - 242.64 |
|---|
| Volume: | 1,440,775 |
|---|
| Avg Vol (3m): | 1,484,940 |
|---|
| Market Cap: | 50.04B |
|---|
| P/E (ttm): | 33.45 |
|---|
| EPS (ttm): | 6.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Royalty drops hostile bid for Ireland's ElanReuters(Tue, 18 Jun)
- Elan holders OK buyback, vote down 3 dealsAP(Tue, 18 Jun)
- Drugmaker Elan plans to explore sale of companyAP(Sat, 15 Jun)
- Movers roundup: Tesla, BiogenAP(Thu, 13 Jun)
- Ahead of the Bell: Analyst lowers Biogen ratingAP(Wed, 12 Jun)
- PDL BioPharma wants arbitration in royalty disputeAP(Wed, 12 Jun)
- Elan rejects Royalty bid, to evaluate other offersAP(Tue, 11 Jun)
- Royalty Pharma raises offer to buy drugmaker ElanAP(Sat, 8 Jun)
- Judge halts Royalty Pharma's bid for Elan stockAP(Wed, 5 Jun)
- Receptos rises as analysts start coverageAP(Tue, 4 Jun)
Key Statistics
| Forward P/E (1 yr): | 20.81 |
|---|
| P/S (ttm): | 8.74 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 8.11 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.90 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 1.32 |
|---|
Business Summary
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally.
View More